Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 12
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Ascendis Pharma AS
ASND
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$227.00
-2.23
-0.97%
Dern. MÀJ: Oct 12, 4:27 PM
$230.50
1.27
0.55%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Ascendis Pharma Financials
Ascendis Pharma (ASND) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M Estimate
Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.78 by 34.62 percent. This is a 212.9 percent increase over losses of $(0.93) per share from
Benzinga Newsdesk
PRO
Ascendis Pharma Q1 Adj. EPS $0.32 Beats $0.21 Estimate, Sales $288.770M Miss $318.050M Estimate
Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 119.28 percent increase over losses of $(1.66) per share from
Benzinga Newsdesk
Ascendis Pharma Earnings Report: Q4 Overview
Benzinga Insights
PRO
Ascendis Pharma Q4 EPS $(0.64) Misses $(0.06) Estimate, Sales $288.127M Miss $289.720M Estimate
Ascendis Pharma (NASDAQ:ASND) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.06) by 966.67 percent. This is a 5.88 percent increase over losses of $(0.68) per share from
Benzinga Newsdesk
Earnings Scheduled For February 11, 2026
Benzinga Insights
A Glimpse of Ascendis Pharma's Earnings Potential
Benzinga Insights
